Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2017

View Archived Issues

Ionis Pharmaceuticals licenses drug to Dynacure

EMA's CHMP supports expanding Nplate indication

Preclinical evaluation of selective ATM kinase AZD-1390 inhibitor for treatment of glioblastoma

EMA committee recommends expanding approval of Orkambi

Discovery of novel ERK1/2 inhibitors with robust antitumor activity in vivo

CHMP issues positive opinion on Avastin biosimilar ABP-215

Neurimmune, Ono Pharmaceutical to collaborate on antibodies for neurodegenerative diseases

Devonian Health Group begins phase IIa study of Thykamine in atopic dermatitis

Benralizumab obtains positive opinion in E.U.

FDA accepts for review Sunovion's NDA for dasotraline

EMA committee confirms refusal of Fanaptum MAA

CFTR potentiator GLPG-2451 appears safe in first-in-human study

FDA expands approval of Bristol-Myers Squibb's Sprycel

Phase III results reported for ozanimod in relapsing MS

EMA grants PRIME designation to Mereo's BPS-804

Pfizer initiates phase I study of pegfilgrastim biosimilar PF-06881894

Wound healing improved with SNF-472 in hemodialysis patients with calciphylaxis

PharmaMar expects negative feedback for Aplidin MAA from EMA committee

University of Massachusetts divulges rAAV vectors encoding aspartoacylase

Novel Bcl-2-targeting drugs created at BioVentures

Dana-Farber Cancer Institute presents new anti-EGFR proteolysis-targeting chimera compounds

Baruch S. Blumberg Institute identifies novel glucosidase inhibitors

Five Prime, GlaxoSmithKline present novel neighbor of punc e11 polypeptides

Actelion studies ACT-709478 in patients with photosensitive epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...